Bionano Genomics heads into the post-earnings session with a story that is harder to dismiss than its micro-cap price suggests — but short sellers have yet to be convinced.
The company reported Q1 2026 earnings after the close on May 13, beating on both lines: EPS came in at $(0.76) against a $(0.95) estimate, and revenue of $6.69 million topped the $6.57 million consensus. Full-year guidance of $30–33 million was affirmed, with Q2 revenue guided to $7.50–$7.80 million. Consumables revenue rose 20% year-over-year to $3.9 million, and flow cells sold hit a record Q1 volume of 8,178 units, up 17% year-over-year. The results land against a messy backdrop: interim CEO Albert Luderer — who is also Chairman — is steering the company through a leadership transition after the departure of long-serving CEO Erik Holmlin.
Short positioning is elevated and has been easing slowly, but the pace of that retreat is the more interesting detail. SI % of FF runs at roughly 11.2% of free float — a meaningful level for a stock trading at $1.26 — yet it has declined steadily from a peak near 12.3% in early April. Over the past month, shorts have trimmed about 5%, and over the week they pulled back another 3%. That directional easing is notable: it began before the earnings beat, not after. Borrow availability is moderate, with approximately half the lending pool already in use — well below the 52-week high utilization of 89%. Cost to borrow has declined sharply over the week, falling more than 25% to 7.9% APR, although it remains elevated relative to early April levels. Taken together, the lending market describes a position that is meaningful but not stressed: bears have been gradually reducing, availability has loosened relative to peak, and borrow costs are trending down.
The ORTEX short score of 69.6 is high in absolute terms but has been essentially flat over the past two weeks — ranging between 68.6 and 70.3. That stability signals no new wave of short building. The short score rank of 11 (11th percentile, meaning more heavily shorted than most peers) is worth noting, but without a fresh acceleration higher it reads as a persistent rather than escalating bear thesis. The factor score picture is thin for a loss-making genomics name: an EPS surprise percentile of just 12 reflects a history of misses, making today's beat a genuine change of direction rather than a routine occurrence.
The institutional holder list reinforces the micro-cap reality. Heights Capital Management holds 10.2% of shares, making it the dominant institutional voice. GSA Capital Partners and Vanguard both modestly added in Q1. No bellwether institution holds a meaningful stake, and recent analyst coverage data is not current enough to cite without risk of misattribution — the most recent valuation multiples in the system are from August 2025 and should not be treated as indicative of today's market pricing.
What gives this setup genuine texture is the reimbursement progress Luderer highlighted on the call. Two Category 1 CPT codes for optical genome mapping are now in effect: one for hematologic malignancies, now paying $1,853 (up 47%), and a new constitutional disorders code at $1,264. Together they cover OGM's primary commercial markets and represent the clearest structural catalyst in the company's history. The $400 million mixed-securities shelf filed on May 8 is a reminder of dilution risk at these prices, but it also signals management is positioning to fund scale rather than simply survive. Against close peers, the week's price action has been bifurcated: BRKR gained 17.7% on the week and RVTY rose 7.6%, while RGEN fell 9.6% and DNA dropped 14.1%. BNGO's 1.6% weekly gain is a modest outperformance relative to the weakest names in the peer set.
The session to watch is the open on May 14, when the market prices in the Q1 beat, the affirmed guidance, and the leadership transition narrative simultaneously.
See the live data behind this article on ORTEX.
Open BNGO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
